Manufacturer with High Quality and Competitive Price
Commercial Supply Aliskiren Related Intermediates:
Aliskiren CAS: 173334-57-1
Aliskiren Hemifumarate CAS: 173334-58-2
(S)-4-Benzyl-2-Oxazolidinone CAS: 90719-32-7
(R)-4-Benzyl-2-Oxazolidinone CAS: 102029-44-7
trans-1,4-Dibromo-2-Butene CAS: 821-06-7
Isovaleryl Chloride CAS: 108-12-3
D-Phenylalanine CAS: 673-06-3
D-Phenylalaninol CAS: 5267-64-1
| Chemical Name |
trans-1,4-Dibromo-2-Butene |
| Synonyms |
(E)-1,4-Dibromobut-2-ene; (2E)-1,4-Dibromo-2-butene |
| CAS Number |
821-06-7 |
| CAT Number |
RF-PI149 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C4H6Br2 |
| Molecular Weight |
213.9 |
| Solubility in Methanol |
Almost Transparency |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White to Brown Solid |
| Purity / Analysis Method |
≥99.0% (GC) |
| Cis Content |
≤0.20% |
| Melting Point |
50.0℃~54.0℃ |
| Tetrabromobutane (TBB) |
≤0.50% |
| Moisture (K.F) |
≤0.20% |
| Test Standard |
Enterprise Standard |
| Usage |
Aliskiren and Aliskiren Hemifumarate Pharmaceutical Intermediate |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of trans-1,4-Dibromo-2-Butene (CAS: 821-06-7) with high quality, widely used in organic synthesis, synthesis of pharmaceutical intermediates and active pharmaceutical ingredient (API) synthesis.
trans-1,4-Dibromo-2-Butene (CAS: 821-06-7) is a key intermediate in the synthesis of Aliskiren (CAS: 173334-57-1), API.
Aliskiren is a first-in-class antihypertensive drug that acts by direct inhibition of renin. It is indicated for oral administration either as monotherapy or in combination with other antihypertensive agents. Renin catalyzes the cleavage of angiotensin to form angiotensin I, the first and the rate-limiting step of the RAAS. The inhibition of renin by aliskiren results in reduced levels of angiotensin I, angiotensin II, and aldosterone, all of which contribute to the antihypertensive effect. RAAS modulators are among some of the most commonly prescribed antihypertensive agents to date.